Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma

Utility of contrast-enhanced agent detection imaging

Chan Kyo Kim, Dongil Choi, Hyo K. Lim, Hoon Kim Seung, Jae Lee Won, Min Ju Kim, Yeon Lee Ji, Hwan Jeon Yong, Jongmee Lee, Jin Lee Soon, Hoon Lim Jae

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Purpose: To assess the utility of contrast-enhanced agent detection imaging (ADI) in the assessment of the therapeutic response to percutaneous radiofrequency (RF) ablation in patients with hepatocellular carcinoma (HCC). Materials and methods: Ninety patients with a total of 97 nodular HCCs (mean, 2.1 ± 1.3 cm; range, 1.0-5.0 cm) treated with percutaneous RF ablation under the ultrasound guidance were evaluated with contrast-enhanced ADI after receiving an intravenous bolus injection of a microbubble contrast agent (SH U 508A). We obtained serial contrast-enhanced ADI images during the time period from 15 to 90 s after the initiation of the bolus contrast injection. All of the patients underwent a follow-up four-phase helical CT at 1 month after RF ablation, which was then repeated at 2-4 month intervals during a period of at least 12 months. The results of the contrast-enhanced ADI were compared with those of the follow-up CT in terms of the presence or absence of residual unablated tumor and local tumor progression in the treated lesions. Results: On contrast-enhanced ADI, technical success was obtained in 94 (97%) of the 97 HCCs, while residual unablated tumors were found in three HCCs (3%). Two of the three tumors that were suspicious (was not proven) for incomplete ablation were subjected to additional RF ablation. The remaining one enhancing lesion that was suspicious of a residual tumor on contrast-enhanced ADI was revealed to be reactive hyperemia at the 1-month follow-up CT. Therefore; the diagnostic concordance between the contrast-enhanced ADI and 1-month follow-up CT was 99%. Of the 94 ablated HCCs without residual tumors on both the contrast-enhanced ADI and 1-month follow-up CT after the initial RF ablation, five (5%) had CT findings of local tumor progression at a subsequent follow-up CT. Conclusion: Despite its limitations in predicting local tumor progression in the treated tumors, contrast-enhanced ADI is potentially useful for evaluating the early therapeutic effect of percutaneous RF ablation for HCCs.

Original languageEnglish
Pages (from-to)66-73
Number of pages8
JournalEuropean Journal of Radiology
Volume56
Issue number1
DOIs
Publication statusPublished - 2005 Oct 1
Externally publishedYes

Fingerprint

Contrast Media
Hepatocellular Carcinoma
Residual Neoplasm
Therapeutics
Neoplasms
Microbubbles
Spiral Computed Tomography
Hyperemia
Therapeutic Uses
Intravenous Injections
Injections

Keywords

  • Agent detection imaging
  • Computed tomography
  • Contrast media
  • Liver neoplasms
  • Radiofrequency ablation
  • Ultrasonography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma : Utility of contrast-enhanced agent detection imaging. / Kim, Chan Kyo; Choi, Dongil; Lim, Hyo K.; Seung, Hoon Kim; Won, Jae Lee; Kim, Min Ju; Ji, Yeon Lee; Yong, Hwan Jeon; Lee, Jongmee; Soon, Jin Lee; Jae, Hoon Lim.

In: European Journal of Radiology, Vol. 56, No. 1, 01.10.2005, p. 66-73.

Research output: Contribution to journalArticle

Kim, Chan Kyo ; Choi, Dongil ; Lim, Hyo K. ; Seung, Hoon Kim ; Won, Jae Lee ; Kim, Min Ju ; Ji, Yeon Lee ; Yong, Hwan Jeon ; Lee, Jongmee ; Soon, Jin Lee ; Jae, Hoon Lim. / Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma : Utility of contrast-enhanced agent detection imaging. In: European Journal of Radiology. 2005 ; Vol. 56, No. 1. pp. 66-73.
@article{12429bb8d2f94b15bfea1ded0a445676,
title = "Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: Utility of contrast-enhanced agent detection imaging",
abstract = "Purpose: To assess the utility of contrast-enhanced agent detection imaging (ADI) in the assessment of the therapeutic response to percutaneous radiofrequency (RF) ablation in patients with hepatocellular carcinoma (HCC). Materials and methods: Ninety patients with a total of 97 nodular HCCs (mean, 2.1 ± 1.3 cm; range, 1.0-5.0 cm) treated with percutaneous RF ablation under the ultrasound guidance were evaluated with contrast-enhanced ADI after receiving an intravenous bolus injection of a microbubble contrast agent (SH U 508A). We obtained serial contrast-enhanced ADI images during the time period from 15 to 90 s after the initiation of the bolus contrast injection. All of the patients underwent a follow-up four-phase helical CT at 1 month after RF ablation, which was then repeated at 2-4 month intervals during a period of at least 12 months. The results of the contrast-enhanced ADI were compared with those of the follow-up CT in terms of the presence or absence of residual unablated tumor and local tumor progression in the treated lesions. Results: On contrast-enhanced ADI, technical success was obtained in 94 (97{\%}) of the 97 HCCs, while residual unablated tumors were found in three HCCs (3{\%}). Two of the three tumors that were suspicious (was not proven) for incomplete ablation were subjected to additional RF ablation. The remaining one enhancing lesion that was suspicious of a residual tumor on contrast-enhanced ADI was revealed to be reactive hyperemia at the 1-month follow-up CT. Therefore; the diagnostic concordance between the contrast-enhanced ADI and 1-month follow-up CT was 99{\%}. Of the 94 ablated HCCs without residual tumors on both the contrast-enhanced ADI and 1-month follow-up CT after the initial RF ablation, five (5{\%}) had CT findings of local tumor progression at a subsequent follow-up CT. Conclusion: Despite its limitations in predicting local tumor progression in the treated tumors, contrast-enhanced ADI is potentially useful for evaluating the early therapeutic effect of percutaneous RF ablation for HCCs.",
keywords = "Agent detection imaging, Computed tomography, Contrast media, Liver neoplasms, Radiofrequency ablation, Ultrasonography",
author = "Kim, {Chan Kyo} and Dongil Choi and Lim, {Hyo K.} and Seung, {Hoon Kim} and Won, {Jae Lee} and Kim, {Min Ju} and Ji, {Yeon Lee} and Yong, {Hwan Jeon} and Jongmee Lee and Soon, {Jin Lee} and Jae, {Hoon Lim}",
year = "2005",
month = "10",
day = "1",
doi = "10.1016/j.ejrad.2005.03.023",
language = "English",
volume = "56",
pages = "66--73",
journal = "European Journal of Radiology",
issn = "0720-048X",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma

T2 - Utility of contrast-enhanced agent detection imaging

AU - Kim, Chan Kyo

AU - Choi, Dongil

AU - Lim, Hyo K.

AU - Seung, Hoon Kim

AU - Won, Jae Lee

AU - Kim, Min Ju

AU - Ji, Yeon Lee

AU - Yong, Hwan Jeon

AU - Lee, Jongmee

AU - Soon, Jin Lee

AU - Jae, Hoon Lim

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Purpose: To assess the utility of contrast-enhanced agent detection imaging (ADI) in the assessment of the therapeutic response to percutaneous radiofrequency (RF) ablation in patients with hepatocellular carcinoma (HCC). Materials and methods: Ninety patients with a total of 97 nodular HCCs (mean, 2.1 ± 1.3 cm; range, 1.0-5.0 cm) treated with percutaneous RF ablation under the ultrasound guidance were evaluated with contrast-enhanced ADI after receiving an intravenous bolus injection of a microbubble contrast agent (SH U 508A). We obtained serial contrast-enhanced ADI images during the time period from 15 to 90 s after the initiation of the bolus contrast injection. All of the patients underwent a follow-up four-phase helical CT at 1 month after RF ablation, which was then repeated at 2-4 month intervals during a period of at least 12 months. The results of the contrast-enhanced ADI were compared with those of the follow-up CT in terms of the presence or absence of residual unablated tumor and local tumor progression in the treated lesions. Results: On contrast-enhanced ADI, technical success was obtained in 94 (97%) of the 97 HCCs, while residual unablated tumors were found in three HCCs (3%). Two of the three tumors that were suspicious (was not proven) for incomplete ablation were subjected to additional RF ablation. The remaining one enhancing lesion that was suspicious of a residual tumor on contrast-enhanced ADI was revealed to be reactive hyperemia at the 1-month follow-up CT. Therefore; the diagnostic concordance between the contrast-enhanced ADI and 1-month follow-up CT was 99%. Of the 94 ablated HCCs without residual tumors on both the contrast-enhanced ADI and 1-month follow-up CT after the initial RF ablation, five (5%) had CT findings of local tumor progression at a subsequent follow-up CT. Conclusion: Despite its limitations in predicting local tumor progression in the treated tumors, contrast-enhanced ADI is potentially useful for evaluating the early therapeutic effect of percutaneous RF ablation for HCCs.

AB - Purpose: To assess the utility of contrast-enhanced agent detection imaging (ADI) in the assessment of the therapeutic response to percutaneous radiofrequency (RF) ablation in patients with hepatocellular carcinoma (HCC). Materials and methods: Ninety patients with a total of 97 nodular HCCs (mean, 2.1 ± 1.3 cm; range, 1.0-5.0 cm) treated with percutaneous RF ablation under the ultrasound guidance were evaluated with contrast-enhanced ADI after receiving an intravenous bolus injection of a microbubble contrast agent (SH U 508A). We obtained serial contrast-enhanced ADI images during the time period from 15 to 90 s after the initiation of the bolus contrast injection. All of the patients underwent a follow-up four-phase helical CT at 1 month after RF ablation, which was then repeated at 2-4 month intervals during a period of at least 12 months. The results of the contrast-enhanced ADI were compared with those of the follow-up CT in terms of the presence or absence of residual unablated tumor and local tumor progression in the treated lesions. Results: On contrast-enhanced ADI, technical success was obtained in 94 (97%) of the 97 HCCs, while residual unablated tumors were found in three HCCs (3%). Two of the three tumors that were suspicious (was not proven) for incomplete ablation were subjected to additional RF ablation. The remaining one enhancing lesion that was suspicious of a residual tumor on contrast-enhanced ADI was revealed to be reactive hyperemia at the 1-month follow-up CT. Therefore; the diagnostic concordance between the contrast-enhanced ADI and 1-month follow-up CT was 99%. Of the 94 ablated HCCs without residual tumors on both the contrast-enhanced ADI and 1-month follow-up CT after the initial RF ablation, five (5%) had CT findings of local tumor progression at a subsequent follow-up CT. Conclusion: Despite its limitations in predicting local tumor progression in the treated tumors, contrast-enhanced ADI is potentially useful for evaluating the early therapeutic effect of percutaneous RF ablation for HCCs.

KW - Agent detection imaging

KW - Computed tomography

KW - Contrast media

KW - Liver neoplasms

KW - Radiofrequency ablation

KW - Ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=24944508661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944508661&partnerID=8YFLogxK

U2 - 10.1016/j.ejrad.2005.03.023

DO - 10.1016/j.ejrad.2005.03.023

M3 - Article

VL - 56

SP - 66

EP - 73

JO - European Journal of Radiology

JF - European Journal of Radiology

SN - 0720-048X

IS - 1

ER -